Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32233956,tmax,"Pharmacokinetic parameters of d-amphetamine, a major active metabolite of LDX, were characterized: d-amphetamine exposure increased with LDX dose; mean tmax and t1/2, respectively, ranged from 4.00 to 4.23 hours and 7.18 to 8.46 hours.",Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233956/),h,4.00 to 4.23,490,DB01576,Dextroamphetamine
,32233956,t1/2,"Pharmacokinetic parameters of d-amphetamine, a major active metabolite of LDX, were characterized: d-amphetamine exposure increased with LDX dose; mean tmax and t1/2, respectively, ranged from 4.00 to 4.23 hours and 7.18 to 8.46 hours.",Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233956/),h,7.18 to 8.46,491,DB01576,Dextroamphetamine
,29620701,tmax,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,6.0,3336,DB01576,Dextroamphetamine
,29620701,tmax,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,6.3,3337,DB01576,Dextroamphetamine
,29620701,t1/2,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,11,3338,DB01576,Dextroamphetamine
,29620701,t1/2,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,12,3339,DB01576,Dextroamphetamine
,29620701,CSSmax,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],100,3340,DB01576,Dextroamphetamine
,29620701,CSSmax,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],58.4,3341,DB01576,Dextroamphetamine
,29620701,CSSmin,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],39.5,3342,DB01576,Dextroamphetamine
,29620701,CSSmin,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],21.8,3343,DB01576,Dextroamphetamine
,10391421,weight,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22460,DB01576,Dextroamphetamine
,10391421,weight-,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22461,DB01576,Dextroamphetamine
,10391421,dose-normalized serum concentrations,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22462,DB01576,Dextroamphetamine
,10391421,dose-normalized serum concentrations,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],39.02,22463,DB01576,Dextroamphetamine
,10391421,clearance,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[l] / [kg],0.690,22464,DB01576,Dextroamphetamine
,10391421,clearance,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[l] / [kg],0.613,22465,DB01576,Dextroamphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.84,26928,DB01576,Dextroamphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,3.05,26929,DB01576,Dextroamphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.52,26930,DB01576,Dextroamphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.75,26931,DB01576,Dextroamphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.48,26932,DB01576,Dextroamphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.65,26933,DB01576,Dextroamphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.55,26934,DB01576,Dextroamphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.72,26935,DB01576,Dextroamphetamine
,31809216,Tmax,Mean ± SD Tmax for AMP (d-AMP; l-AMP) was higher with intact capsule and meal (5.59 ± 1.57; 5.59 ± 1.59) versus fasted (2.85 ± 0.76; 2.97 ± 0.79).,"Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,5.59,26936,DB01576,Dextroamphetamine
,31809216,Tmax,Mean ± SD Tmax for AMP (d-AMP; l-AMP) was higher with intact capsule and meal (5.59 ± 1.57; 5.59 ± 1.59) versus fasted (2.85 ± 0.76; 2.97 ± 0.79).,"Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,5.59,26937,DB01576,Dextroamphetamine
,31809216,Tmax,Mean ± SD Tmax for AMP (d-AMP; l-AMP) was higher with intact capsule and meal (5.59 ± 1.57; 5.59 ± 1.59) versus fasted (2.85 ± 0.76; 2.97 ± 0.79).,"Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.85,26938,DB01576,Dextroamphetamine
,31809216,Tmax,Mean ± SD Tmax for AMP (d-AMP; l-AMP) was higher with intact capsule and meal (5.59 ± 1.57; 5.59 ± 1.59) versus fasted (2.85 ± 0.76; 2.97 ± 0.79).,"Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.97,26939,DB01576,Dextroamphetamine
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],45.0,38540,DB01576,Dextroamphetamine
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],713.0,38541,DB01576,Dextroamphetamine
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38542,DB01576,Dextroamphetamine
,19820270,Cmax,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],46.3,38543,DB01576,Dextroamphetamine
,19820270,Cmax,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38544,DB01576,Dextroamphetamine
,19820270,AUCinf,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38545,DB01576,Dextroamphetamine
,19820270,Tmax,The median Tmax was 3 hours with and without omeprazole.,Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,3,38546,DB01576,Dextroamphetamine
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],36.6,38547,DB01576,Dextroamphetamine
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],640.8,38548,DB01576,Dextroamphetamine
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38549,DB01576,Dextroamphetamine
,19820270,Cmax,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],38.1,38550,DB01576,Dextroamphetamine
,19820270,Cmax,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38551,DB01576,Dextroamphetamine
,19820270,AUCinf,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38552,DB01576,Dextroamphetamine
,19820270,Tmax,"The median Tmax was 5 hours and 2.75 hours without and with omeprazole, respectively; 57.1% to 61.9% of subjects receiving MAS XR and 25% receiving LDX showed an earlier (>or= 1 hour) Tmax with omeprazole.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,5,38553,DB01576,Dextroamphetamine
,19820270,Tmax,"The median Tmax was 5 hours and 2.75 hours without and with omeprazole, respectively; 57.1% to 61.9% of subjects receiving MAS XR and 25% receiving LDX showed an earlier (>or= 1 hour) Tmax with omeprazole.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,2.75,38554,DB01576,Dextroamphetamine
,20173084,time to C(max),Median time to C(max) ranged from 4 to 6 hours for d-amphetamine and 1.0 to 1.5 hours for lisdexamfetamine dimesylate.,"Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173084/),h,4 to 6,40695,DB01576,Dextroamphetamine
,20173084,time to C(max),Median time to C(max) ranged from 4 to 6 hours for d-amphetamine and 1.0 to 1.5 hours for lisdexamfetamine dimesylate.,"Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173084/),h,1.0 to 1.5,40696,DB01576,Dextroamphetamine
,18991468,time to reach maximum plasma drug concentration (t(max)),"For intact lisdexamfetamine dimesylate, the median time to reach maximum plasma drug concentration (t(max)) was 1.00 hour, and the mean maximum plasma drug concentration (C(max)) was 58.2 +/- 28.1 ng/mL.","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),h,1.00,43787,DB01576,Dextroamphetamine
,18991468,maximum plasma drug concentration (C(max)),"For intact lisdexamfetamine dimesylate, the median time to reach maximum plasma drug concentration (t(max)) was 1.00 hour, and the mean maximum plasma drug concentration (C(max)) was 58.2 +/- 28.1 ng/mL.","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),[ng] / [ml],58.2,43788,DB01576,Dextroamphetamine
,18991468,area under the drug concentration-time curve from time 0 to infinity [AUC(infinity)],"Intact lisdexamfetamine dimesylate exhibited modest systemic exposure (area under the drug concentration-time curve from time 0 to infinity [AUC(infinity)] 67.04 +/- 18.94 ng . h/mL), and rapid elimination (mean apparent terminal elimination half-life [t((1/2)beta)] 0.47 hours).","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),[h·ng] / [ml],67.04,43789,DB01576,Dextroamphetamine
,18991468,apparent terminal elimination half-life [t((1/2)beta)],"Intact lisdexamfetamine dimesylate exhibited modest systemic exposure (area under the drug concentration-time curve from time 0 to infinity [AUC(infinity)] 67.04 +/- 18.94 ng . h/mL), and rapid elimination (mean apparent terminal elimination half-life [t((1/2)beta)] 0.47 hours).","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),h,0.47,43790,DB01576,Dextroamphetamine
,18991468,t(max),"For d-amphetamine, the median t(max) was 3.00 hours, and the mean C(max) was 80.3 +/- 11.8 ng/mL.","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),h,3.00,43791,DB01576,Dextroamphetamine
,18991468,C(max),"For d-amphetamine, the median t(max) was 3.00 hours, and the mean C(max) was 80.3 +/- 11.8 ng/mL.","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),[ng] / [ml],80.3,43792,DB01576,Dextroamphetamine
,18991468,AUC(infinity),The AUC(infinity) of d-amphetamine was 1342 +/- 216.9 ng .,"Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),ng,1342,43793,DB01576,Dextroamphetamine
,18991468,t((1/2)beta),The t((1/2)beta) of d-amphetamine was 10.39 hours.,"Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),h,10.39,43794,DB01576,Dextroamphetamine
,17452029,flow rate,"Reverse-phase HPLC separation was accomplished on a Zorbax SB-C18 column (100 mm x 3.0 mm, 3.5 microm) with a mobile phase composed of methanol-water-formic acid (65:35:0.5, v/v/v) at a flow rate of 0.2 mL/min.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),[ml] / [min],0.2,43873,DB01576,Dextroamphetamine
,17452029,total run time,The method had a chromatographic total run time of 5 min.,Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),min,5,43874,DB01576,Dextroamphetamine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,136.0,43875,DB01576,Dextroamphetamine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,91.0,43876,DB01576,Dextroamphetamine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,256.0,43877,DB01576,Dextroamphetamine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,166.1,43878,DB01576,Dextroamphetamine
,18285619,t(max),The t(max) of d-amphetamine and intact lisdexamfetamine was similar when taken in solution or in the fasted state but was about 1 hour longer when taken with food.,"Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18285619/),h,1,49318,DB01576,Dextroamphetamine
,27935735,"area under the plasma concentration versus time curve, AUC","LDX levels peaked at 1.5 hours after administration (Tmax) and then rapidly declined (levels were negligible at 6 hours and area under the plasma concentration versus time curve, AUC = 45.9, Cmax = 25.0, and half-life [t1/2] = 0.5 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),,45.9,52816,DB01576,Dextroamphetamine
,27935735,Cmax,"LDX levels peaked at 1.5 hours after administration (Tmax) and then rapidly declined (levels were negligible at 6 hours and area under the plasma concentration versus time curve, AUC = 45.9, Cmax = 25.0, and half-life [t1/2] = 0.5 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,25.0,52817,DB01576,Dextroamphetamine
,27935735,half-life [t1/2],"LDX levels peaked at 1.5 hours after administration (Tmax) and then rapidly declined (levels were negligible at 6 hours and area under the plasma concentration versus time curve, AUC = 45.9, Cmax = 25.0, and half-life [t1/2] = 0.5 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,0.5,52818,DB01576,Dextroamphetamine
,27935735,Tmax),"Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,4.4,52819,DB01576,Dextroamphetamine
,27935735,AUC,"Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,641.6,52820,DB01576,Dextroamphetamine
,27935735,Cmax,"Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,67.9,52821,DB01576,Dextroamphetamine
,27935735,t1/2,"Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,17.0,52822,DB01576,Dextroamphetamine
,14520168,terminal half life time,"The median terminal half life time was 14.3 hours (inter quartile range, IQR: 11.9-6.9), 13.1 (IQR: 10.8-15.9) and 14.0 (IQR: 7.4-16.4) in the 2.5 mg, 5 mg, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),h,14.3,56377,DB01576,Dextroamphetamine
,14520168,terminal half life time,"The median terminal half life time was 14.3 hours (inter quartile range, IQR: 11.9-6.9), 13.1 (IQR: 10.8-15.9) and 14.0 (IQR: 7.4-16.4) in the 2.5 mg, 5 mg, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),h,13.1,56378,DB01576,Dextroamphetamine
,14520168,terminal half life time,"The median terminal half life time was 14.3 hours (inter quartile range, IQR: 11.9-6.9), 13.1 (IQR: 10.8-15.9) and 14.0 (IQR: 7.4-16.4) in the 2.5 mg, 5 mg, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),h,14.0,56379,DB01576,Dextroamphetamine
,14520168,maximal plasma concentration (Cmax),"The median maximal plasma concentration (Cmax) was 6.6 ng/mL (IQR: 5.1-7.0), 11.6 (IQR: 7.8-12.8), and 16.9 (IQR: 14.9-20.2) in the 2.5 mg, 5 mg, and the 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),[ng] / [ml],6.6,56380,DB01576,Dextroamphetamine
,14520168,maximal plasma concentration (Cmax),"The median maximal plasma concentration (Cmax) was 6.6 ng/mL (IQR: 5.1-7.0), 11.6 (IQR: 7.8-12.8), and 16.9 (IQR: 14.9-20.2) in the 2.5 mg, 5 mg, and the 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),[ng] / [ml],11.6,56381,DB01576,Dextroamphetamine
,14520168,maximal plasma concentration (Cmax),"The median maximal plasma concentration (Cmax) was 6.6 ng/mL (IQR: 5.1-7.0), 11.6 (IQR: 7.8-12.8), and 16.9 (IQR: 14.9-20.2) in the 2.5 mg, 5 mg, and the 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),[ng] / [ml],16.9,56382,DB01576,Dextroamphetamine
,14520168,time to Cmax (Tmax),"The median time to Cmax (Tmax) was 1.83 hours (IQR: 1.79-3.94), 2.59 (IQR: 1.32-3.83), and 3.86 (IQR: 1.82-5.77) in the 2.5, 5, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),h,1.83,56383,DB01576,Dextroamphetamine
,14520168,time to Cmax (Tmax),"The median time to Cmax (Tmax) was 1.83 hours (IQR: 1.79-3.94), 2.59 (IQR: 1.32-3.83), and 3.86 (IQR: 1.82-5.77) in the 2.5, 5, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),,2.59,56384,DB01576,Dextroamphetamine
,14520168,time to Cmax (Tmax),"The median time to Cmax (Tmax) was 1.83 hours (IQR: 1.79-3.94), 2.59 (IQR: 1.32-3.83), and 3.86 (IQR: 1.82-5.77) in the 2.5, 5, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),,3.86,56385,DB01576,Dextroamphetamine
,25310201,maximum plasma concentration,"With ascending LDX dose, the mean (SD) maximum plasma concentration for LDX-derived d-amphetamine ranged from 51.68 (10.28) to 266.27 (56.55) ng/mL.","Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25310201/),[ng] / [ml],51.68,106953,DB01576,Dextroamphetamine
,25310201,maximum plasma concentration,"With ascending LDX dose, the mean (SD) maximum plasma concentration for LDX-derived d-amphetamine ranged from 51.68 (10.28) to 266.27 (56.55) ng/mL.","Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25310201/),[ng] / [ml],266.27,106954,DB01576,Dextroamphetamine
,25310201,area under the plasma concentration-time curve for 24 hours,The area under the plasma concentration-time curve for 24 hours ranged from 801.8 (170.2) to 4397.9 (1085.9) ng[BULLET OPERATOR]h/mL.,"Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25310201/),ng,801.8,106955,DB01576,Dextroamphetamine
,25310201,area under the plasma concentration-time curve for 24 hours,The area under the plasma concentration-time curve for 24 hours ranged from 801.8 (170.2) to 4397.9 (1085.9) ng[BULLET OPERATOR]h/mL.,"Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25310201/),ng,4397.9,106956,DB01576,Dextroamphetamine
,22039171,maximal plasma concentration (C(max)),"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),[ng] / [ml],37.6,135862,DB01576,Dextroamphetamine
,22039171,maximal plasma concentration (C(max)),"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),[ng] / [ml],40.5,135863,DB01576,Dextroamphetamine
,22039171,maximal plasma concentration (C(max)),"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),[ng] / [ml],38.7,135864,DB01576,Dextroamphetamine
,22039171,maximal plasma concentration (C(max)),"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),[ng] / [ml],25.7,135865,DB01576,Dextroamphetamine
,22039171,area under the concentration-time curve to the last measurable time point,"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h·ml⁻¹·ng,719.1,135866,DB01576,Dextroamphetamine
,22039171,area under the concentration-time curve to the last measurable time point,"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h·ml⁻¹·ng,771.2,135867,DB01576,Dextroamphetamine
,22039171,area under the concentration-time curve to the last measurable time point,"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h·ml⁻¹·ng,752.4,135868,DB01576,Dextroamphetamine
,22039171,area under the concentration-time curve to the last measurable time point,"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h·ml⁻¹·ng,574.3,135869,DB01576,Dextroamphetamine
,22039171,time to C(max),"Median time to C(max) was 5, 4, 5, and 8 h, respectively.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h,5,135870,DB01576,Dextroamphetamine
,22039171,time to C(max),"Median time to C(max) was 5, 4, 5, and 8 h, respectively.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h,4,135871,DB01576,Dextroamphetamine
,22039171,time to C(max),"Median time to C(max) was 5, 4, 5, and 8 h, respectively.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h,8,135872,DB01576,Dextroamphetamine
,18021493,steady-state d,"Based on C(min), steady-state d-amphetamine concentration (20.6 ng/mL) was reached by day 5, whereas LDX was undetectable, and 95% of the d-amphetamine was eliminated within 48 hours following the final dose on day 7.",Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021493/),[ng] / [ml],20.6,137648,DB01576,Dextroamphetamine
,18021493,C(max),"At steady state, d-amphetamine achieved a mean +/- standard deviation C(max) of 90.1 +/- 29.6 ng/mL, with a median T(max) of 3.0 hours.",Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021493/),[ng] / [ml],90.1,137649,DB01576,Dextroamphetamine
,18021493,T(max),"At steady state, d-amphetamine achieved a mean +/- standard deviation C(max) of 90.1 +/- 29.6 ng/mL, with a median T(max) of 3.0 hours.",Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021493/),h,3.0,137650,DB01576,Dextroamphetamine
,18021493,AUC(0-inf),The AUC(0-inf) for d-amphetamine was 1453 +/- 645.7 ng.h/mL.,Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021493/),[h·ng] / [ml],1453,137651,DB01576,Dextroamphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,79,151609,DB01576,Dextroamphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,67,151610,DB01576,Dextroamphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,37.4,151611,DB01576,Dextroamphetamine
,14586388,elimination half-life,"The elimination half-life was similar for intravenous (11.4 hours), intranasal (10.7 hours), and smoked (10.7 hours) methamphetamine.",The bioavailability of intranasal and smoked methamphetamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,11.4,151612,DB01576,Dextroamphetamine
,14586388,elimination half-life,"The elimination half-life was similar for intravenous (11.4 hours), intranasal (10.7 hours), and smoked (10.7 hours) methamphetamine.",The bioavailability of intranasal and smoked methamphetamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,10.7,151613,DB01576,Dextroamphetamine
,14586388,Clearance,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],272,151614,DB01576,Dextroamphetamine
,14586388,steady-state volume of distribution,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[l] / [kg],4.2,151615,DB01576,Dextroamphetamine
,14586388,mean residence time,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,16,151616,DB01576,Dextroamphetamine
,14586388,half-life,"Dextroamphetamine (INN, dexamfetamine) half-life (all routes) was 16.2 hours.",The bioavailability of intranasal and smoked methamphetamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,16.2,151617,DB01576,Dextroamphetamine
,14586388,renal clearances,"Methamphetamine and dextroamphetamine renal clearances (all routes) were about 100 and 1100 mL x h(-1) x kg(-1), respectively.",The bioavailability of intranasal and smoked methamphetamine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],100,151618,DB01576,Dextroamphetamine
,14586388,renal clearances,"Methamphetamine and dextroamphetamine renal clearances (all routes) were about 100 and 1100 mL x h(-1) x kg(-1), respectively.",The bioavailability of intranasal and smoked methamphetamine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],1100,151619,DB01576,Dextroamphetamine
,12921476,Time to maximum concentration (Tmax),"Time to maximum concentration (Tmax) for SLI381 versus Adderall showed average increases of 3.0 hours for dextroamphetamine (t = -2.35, p = .04, df = 8.6) and 3.2 hours for levoamphetamine (t = -2.39, p = .04, df = 9.2).","Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12921476/),h,3.0,155763,DB01576,Dextroamphetamine
,12921476,Time to maximum concentration (Tmax),"Time to maximum concentration (Tmax) for SLI381 versus Adderall showed average increases of 3.0 hours for dextroamphetamine (t = -2.35, p = .04, df = 8.6) and 3.2 hours for levoamphetamine (t = -2.39, p = .04, df = 9.2).","Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12921476/),h,3.2,155764,DB01576,Dextroamphetamine
,26329917,Absorption rate constant,"Absorption rate constant, clearance, and volume of distribution for the plasma compartment were estimated as 0.527 h(-1) (95% CI 0.467-0.586), 28.7 L/h (95% CI 27.1-30.3), and 377 L (95% CI 326-428), respectively.",A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),1/[h],0.527,172150,DB01576,Dextroamphetamine
,26329917,clearance,"Absorption rate constant, clearance, and volume of distribution for the plasma compartment were estimated as 0.527 h(-1) (95% CI 0.467-0.586), 28.7 L/h (95% CI 27.1-30.3), and 377 L (95% CI 326-428), respectively.",A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),[l] / [h],28.7,172151,DB01576,Dextroamphetamine
,26329917,volume of distribution for the,"Absorption rate constant, clearance, and volume of distribution for the plasma compartment were estimated as 0.527 h(-1) (95% CI 0.467-0.586), 28.7 L/h (95% CI 27.1-30.3), and 377 L (95% CI 326-428), respectively.",A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),l,377,172152,DB01576,Dextroamphetamine
,26329917,incorporation rate constant,The incorporation rate constant from plasma to hair was 1.60e(-6) h(-1) (95% CI 1.06e(-6)-2.14e(-6)) and apparent volume of distribution in hair was 17.7 mg (95% CI 12.5-22.8).,A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),1/[(e)^6·h],1.60,172153,DB01576,Dextroamphetamine
,26329917,apparent volume of distribution,The incorporation rate constant from plasma to hair was 1.60e(-6) h(-1) (95% CI 1.06e(-6)-2.14e(-6)) and apparent volume of distribution in hair was 17.7 mg (95% CI 12.5-22.8).,A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),mg,17.7,172154,DB01576,Dextroamphetamine
,111276,apparent elimination half-life,"Sixteen male children who scored greater than 2SD from norms on Factors I and IV of Conner's Teacher Rating Scale and who were not excluded for reasons to do with medical or psychiatric conditions, intelligence, or age, had a plasma d-amphetamine apparent elimination half-life of 6.8 +/- 0.5h.",Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/111276/),h,6.8,185735,DB01576,Dextroamphetamine
,111276,Peak plasma level,"Peak plasma level occurred between 3 and 4h (62.7 +/- 3.8 and 65.9 +/- 3.6 ng/ml, respectively).",Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/111276/),[ng] / [ml],62.7,185736,DB01576,Dextroamphetamine
,111276,Peak plasma level,"Peak plasma level occurred between 3 and 4h (62.7 +/- 3.8 and 65.9 +/- 3.6 ng/ml, respectively).",Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/111276/),[ng] / [ml],65.9,185737,DB01576,Dextroamphetamine
,20206783,C(max),"Mean (%CV) C(max) values of d-amphetamine postdose were 53.2 (18.1), 93.3 (19.5), and 134.0 (19.4) ng/mL with LDX 30, 50, and 70 mg, respectively (T(max), approximately 3.5 hours).","Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206783/),[ng] / [ml],53.2,187017,DB01576,Dextroamphetamine
,20206783,C(max),"Mean (%CV) C(max) values of d-amphetamine postdose were 53.2 (18.1), 93.3 (19.5), and 134.0 (19.4) ng/mL with LDX 30, 50, and 70 mg, respectively (T(max), approximately 3.5 hours).","Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206783/),[ng] / [ml],93.3,187018,DB01576,Dextroamphetamine
,20206783,C(max),"Mean (%CV) C(max) values of d-amphetamine postdose were 53.2 (18.1), 93.3 (19.5), and 134.0 (19.4) ng/mL with LDX 30, 50, and 70 mg, respectively (T(max), approximately 3.5 hours).","Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206783/),[ng] / [ml],134.0,187019,DB01576,Dextroamphetamine
,20206783,T(max),"Mean (%CV) C(max) values of d-amphetamine postdose were 53.2 (18.1), 93.3 (19.5), and 134.0 (19.4) ng/mL with LDX 30, 50, and 70 mg, respectively (T(max), approximately 3.5 hours).","Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206783/),h,3.5,187020,DB01576,Dextroamphetamine
,21539403,maximum observed plasma concentration (C(max)),"The mean ± SD maximum observed plasma concentration (C(max)) and area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)) of d-amphetamine following PO administration of lisdexamfetamine dimesylate were 37.6 ± 4.54 ng/mL and 719.1 ± 157.05 ng · h/mL, respectively; after IN administration, these parameters were 35.9 ± 6.49 ng/mL and 690.5 ± 157.05 ng · h/mL, respectively.","Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),[ng] / [ml],37.6,213070,DB01576,Dextroamphetamine
,21539403,maximum observed plasma concentration (C(max)),"The mean ± SD maximum observed plasma concentration (C(max)) and area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)) of d-amphetamine following PO administration of lisdexamfetamine dimesylate were 37.6 ± 4.54 ng/mL and 719.1 ± 157.05 ng · h/mL, respectively; after IN administration, these parameters were 35.9 ± 6.49 ng/mL and 690.5 ± 157.05 ng · h/mL, respectively.","Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),[ng] / [ml],35.9,213071,DB01576,Dextroamphetamine
,21539403,area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)),"The mean ± SD maximum observed plasma concentration (C(max)) and area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)) of d-amphetamine following PO administration of lisdexamfetamine dimesylate were 37.6 ± 4.54 ng/mL and 719.1 ± 157.05 ng · h/mL, respectively; after IN administration, these parameters were 35.9 ± 6.49 ng/mL and 690.5 ± 157.05 ng · h/mL, respectively.","Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),[h·ng] / [ml],719.1,213072,DB01576,Dextroamphetamine
,21539403,area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)),"The mean ± SD maximum observed plasma concentration (C(max)) and area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)) of d-amphetamine following PO administration of lisdexamfetamine dimesylate were 37.6 ± 4.54 ng/mL and 719.1 ± 157.05 ng · h/mL, respectively; after IN administration, these parameters were 35.9 ± 6.49 ng/mL and 690.5 ± 157.05 ng · h/mL, respectively.","Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),[h·ng] / [ml],690.5,213073,DB01576,Dextroamphetamine
,21539403,time to reach C(max) (t(max)),PO and IN administration demonstrated similar median time to reach C(max) (t(max)) for d-amphetamine: 5 hours for PO administration versus 4 hours for IN administration.,"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),h,5,213074,DB01576,Dextroamphetamine
,21539403,time to reach C(max) (t(max)),PO and IN administration demonstrated similar median time to reach C(max) (t(max)) for d-amphetamine: 5 hours for PO administration versus 4 hours for IN administration.,"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),h,4,213075,DB01576,Dextroamphetamine
,21539403,elimination half-life (t(1/2)),Mean ± SD elimination half-life (t(1/2)) values were also similar for PO (11.6 ± 2.8 hours) and IN (11.3 ± 1.8 hours) lisdexamfetamine dimesylate.,"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),h,11.6,213076,DB01576,Dextroamphetamine
,21539403,elimination half-life (t(1/2)),Mean ± SD elimination half-life (t(1/2)) values were also similar for PO (11.6 ± 2.8 hours) and IN (11.3 ± 1.8 hours) lisdexamfetamine dimesylate.,"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),h,11.3,213077,DB01576,Dextroamphetamine
,16344836,Tmax,"Tmax was 4.2 and 4.3 hours for d-amphetamine to l-amphetamine, respectively.",Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344836/),h,4.2,232028,DB01576,Dextroamphetamine
,16344836,Tmax,"Tmax was 4.2 and 4.3 hours for d-amphetamine to l-amphetamine, respectively.",Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344836/),h,4.3,232029,DB01576,Dextroamphetamine
,16344836,Tmax,"In Study B, for d- and l-amphetamine, statistically significant differences were observed for AUC0-t, AUC0-inf, and Cmax between all doses; there was a linear relationship between pharmacokinetic variables and dose and Tmax was similar for each isomer (range: 4.5-5.3 hours) with all given MAS XR doses.",Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344836/),h,4.5-5.3,232030,DB01576,Dextroamphetamine
,7636721,peak plasma,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),μM,1.7,246902,DB01576,Dextroamphetamine
,7636721,peak plasma,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,36,246903,DB01576,Dextroamphetamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),μM,2.9,246904,DB01576,Dextroamphetamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,73,246905,DB01576,Dextroamphetamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,25,246906,DB01576,Dextroamphetamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,50,246907,DB01576,Dextroamphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5370,262206,DB01576,Dextroamphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5246,262207,DB01576,Dextroamphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.43,262208,DB01576,Dextroamphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.87,262209,DB01576,Dextroamphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.23,262210,DB01576,Dextroamphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.11,262211,DB01576,Dextroamphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],677.9,262212,DB01576,Dextroamphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],466.9,262213,DB01576,Dextroamphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,207",262214,DB01576,Dextroamphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,688",262215,DB01576,Dextroamphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],34.85,262216,DB01576,Dextroamphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],37.27,262217,DB01576,Dextroamphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],92.07,262218,DB01576,Dextroamphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],93.04,262219,DB01576,Dextroamphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1428,262220,DB01576,Dextroamphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1499,262221,DB01576,Dextroamphetamine
